IONS240920P60000
- 20.80
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Jefferies Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Jefferies analyst Akash Tewari maintains $Ionis Pharmaceuticals(IONS.US)$ with a buy rating, and maintains the target price at $77.According to TipRanks data, the analyst has a success rate of 58.0%
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Leerink Partners Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $56
Leerink Partners analyst Mani Foroohar maintains $Ionis Pharmaceuticals(IONS.US)$ with a buy rating, and sets the target price at $56.According to TipRanks data, the analyst has a success rate of 40.1
Ionis Pharmaceuticals: A Buy Rating With a Lowered Price Target Amidst Strong Growth Prospects
Ionis Pharmaceuticals Down Over 10%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Unusual Options Activity: OVV, KKR and Others Attract Market Bets, OVV V/OI Ratio Reaches 190.3
EST Sep 10th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Ionis Pharmaceuticals Shares Are Trading Lower After the Company Priced Its $500.3 Million Public Offering of 11.5 Million Common Shares at $43.50 per Share.
S&P 500 Futures Steady In Premarket Trading; Oracle, Sonoco Products Lead
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $56 From $62
Ionis Shares Drop on Discounted Public Offering
Ionis Prices Underwritten Public Offering of 11.5M Shares at $43.50 Each >IONS
Ionis Announces Pricing of $500.3 Million Public Offering
Ionis Pharmaceuticals Plans $500 Million Common Stock Offering
Ionis Announces Proposed Public Offering of Common Stock
Biogen Says Trial of Potential Treatment for Infant Spinal Muscular Atrophy Meets Primary Endpoint